| |OCTOBER 202319junctures, such as the recent outbreak of conjunctivitis, where it distributed 1 million vials of eye drops and 10 million injections per day across the length and breadth of India. "Laborate has demonstrated its commitment to meet diverse healthcare needs as healthcare is not a privilege, but a basic human right", adds Sanjay Bhatia, Director of Laborate. The Transition to Branded GenericsA pivotal juncture in Laborate Pharmaceuticals' trajectory is marked by its strategic shift from generic medicines to branded generics. This transition reflects the company's astute responsiveness to evolving regulations, such as the National Medical Council's directive to prescribe medicines by its generic names rather than brand names. Recognizing the increasing influence wielded by retailers and wholesalers in the prescription process, Laborate Pharmaceuticals proactively focuses on nurturing these relationships, aligning its strategy with the changing dynamics of the industry. This adaptability and forward-looking approach have become emblematic of the company's ethos. Diversification emerges as a key pillar of Laborate Pharmaceuticals' growth strategy. The company has effectively ventured into multiple segments, including analgesics, antibiotics, cardi-vscular, corticosteroids, NSAIDS, Anti-allergic, Anti-asthametic, Psychotropic, Liquid injections, Eye/ear drops, Derma products, and more. The entire product range covers approximately 1000 products. This strategic expansion highlights Laborate's ability to explore new horizons while steadfastly upholding its core commitment to delivering quality healthcare solutions at affordable prices. The Company's upcoming venture into the European Union not only signifies a significant leap forward but also underscores its dedication to adhering to the stringent regulatory standards of this prominent market. This foray exemplifies the company's ambition to further expand its reach and impact on a global scale.Precision through TechnologyThe success of Laborate Pharmaceuticals can be attributed with company's constant dedication to increase its production capacity with improvised technology. Laborate is coming with a new state of art manufacturing plant in 8,50,000 square feet land. This plant is equipped with fully automatic machines with no human touch for OSD & injection with a capacity of 20 million tablets, 10 million capsules & 2 million injections in a day. Company has aim to open European & Australia market with this regulated plant. One of the most striking facets is the company's unwavering investment in quality control. Boasting an impressive array of 37 High-Performance Liquid Chromatography (HPLC) units, Laborate Pharmaceuticals employs cutting-edge technology to ensure the quality and efficacy of its products. Moreover, the state-of-the-art micro lab stands as a testament to the company's unyielding commitment to delivering safe and reliable medicines, with minimal risk of contamination. The strong and enduring relationships that Laborate Pharmaceuticals maintains with its vendors contribute significantly to its success story. "By 2028, we aim to achieve a turnover of 4000 Cr and plan to expand into Animal healthcare", adds Ajay Bhatia, Chairman.Beyond its products and processes, Laborate Pharmaceuticals' emphasis on people is evident in every facet of its operations. With an employee base numbering between 3,000 to 4,000 individuals, the company recognizes its responsibility towards numerous families. This deep-rooted sense of duty extends to channel partners and customers, as exemplified by initiatives like the Fundose event. Going beyond a mere celebration of achievements, this annual event serves as a platform for motivation and empowerment, fostering a sense of belonging and community.Future ProjectionsAs Laborate Pharmaceuticals casts its gaze toward the future, the horizon appears luminous with possibilities. In the domestic market, the company aims to fortify its position as a leading player in the generic pharmaceutical segment while concurrently expanding its footprint in the realm of branded generics. On the international stage, the company's growth trajectory is poised to accelerate, with ambitious plans to enter regulated markets and eventually establish a presence in the highly coveted US market.In a resounding culmination, the saga of Laborate Pharmaceuticals encapsulates the profound essence of a journey marked by vision, unyielding commitment to quality, and the strategic foresight to evolve and adapt. This narrative stands as an inspiring beacon not only for the pharmaceutical industry but for all endeavors, underscoring the transformative power of innovation, the strength of relationships, and the unwavering focus on quality as the cornerstones of enduring success. "With our strong foundation and an unshakable commitment to our core values, we stand poised to chart even more remarkable chapters in the tapestry of our legacy", concludes Arpit Bhatia, Director. POLABORATE PHARMACEUTICALS IS A TOP-TIER GLOBAL COMPANY BRINGING VALUE TO LIVES WITH QUALITY HEALTHCARE
< Page 9 | Page 11 >